UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 540

Sortiert nach

Dasatinib dose management for the treatment of chronic myeloid leukemia

Cancer, 2018-04, Vol.124 (8), p.1660-1672

2018

Link zum Volltext

Verfügbarkeit prüfen

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

The lancet oncology, 2010-11, Vol.11 (11), p.1029-1035

2010

Link zum Volltext

Verfügbarkeit prüfen

Old rivals become new friends

Blood, 2024-02, Vol.143 (5), p.380

Rousselot, Philippe

2024

Link zum Volltext

Verfügbarkeit prüfen

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

American journal of hematology, 2016-09, Vol.91 (9), p.869-874

2016

Link zum Volltext

Verfügbarkeit prüfen

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial

Journal of clinical oncology, 2018-08, Vol.36 (24), p.2514-2523

2018

Link zum Volltext

Verfügbarkeit prüfen

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

Haematologica (Roma), 2019-01, Vol.104 (1), p.93-101

2019

Link zum Volltext

Verfügbarkeit prüfen

BiTtEn by Src inhibitors

Blood, 2021-02, Vol.137 (7), p.867-868

Rousselot, Philippe

2021

Link zum Volltext

Verfügbarkeit prüfen

UV exploration of the solar system

Experimental astronomy, 2022-12, Vol.54 (2-3), p.1169-1186

2022

Link zum Volltext

Verfügbarkeit prüfen

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

British journal of haematology, 2019-11, Vol.187 (3), p.337-346

2019

Link zum Volltext

Verfügbarkeit prüfen

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Blood, 2007-06, Vol.109 (12), p.5143-5150

2007

Link zum Volltext

Verfügbarkeit prüfen

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

Nature Medicine, 2008-12, Vol.14 (12), p.1333-1342

2008

Link zum Volltext

Verfügbarkeit prüfen

Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura

Platelets (Edinburgh), 2022-05, Vol.33 (4), p.652-653

2022

Link zum Volltext

Verfügbarkeit prüfen

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

Journal of hematology and oncology, 2018-12, Vol.11 (1), p.143-143, Article 143

2018

Link zum Volltext

Verfügbarkeit prüfen

TOWARD A UNIQUE NITROGEN ISOTOPIC RATIO IN COMETARY ICES

Astrophysical journal. Letters, 2014-01, Vol.780 (2), p.1-5

2014

Link zum Volltext

Verfügbarkeit prüfen

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Haematologica (Roma), 2010-02, Vol.95 (2), p.232

2010

Link zum Volltext

Verfügbarkeit prüfen

Distant activity of Comet C/2002 VQ94 (LINEAR): Optical spectrophotometric monitoring between 8.4 and 16.8 au from the Sun

Icarus (New York, N.Y. 1962), 2014-04, Vol.232, p.88-96

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 540

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(500)
Mit Volltextzugriff
(503)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(249)
Life Sciences & Biomedicine
(224)
Humans
(195)
Female
(122)
Hematology
(121)
Male
(121)
Middle Aged
(112)
Adult
(101)
Life Sciences
(93)
Aged
(83)
Oncology
(69)
Biological And Medical Sciences
(60)
Medical Sciences
(60)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(50)
Treatment Outcome
(45)
Aged, 80 And Over
(40)
Leukemia
(39)
Hematologic And Hematopoietic Diseases
(37)
Chronic Myeloid Leukemia
(36)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(35)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(174)
Journal Of Clinical Oncology
(22)
Clinical Lymphoma, Myeloma And Leukemia
(17)
British Journal Of Haematology
(14)
Leukemia Research
(12)
Haematologica
(11)
Hématologie
(11)
American Journal Of Hematology
(9)
Astronomy And Astrophysics
(7)
Hemasphere
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Dasatinib dose management for the treatment of chronic myeloid leukemia

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

Old rivals become new friends

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

BiTtEn by Src inhibitors

UV exploration of the solar system

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

TOWARD A UNIQUE NITROGEN ISOTOPIC RATIO IN COMETARY ICES

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study

Distant activity of Comet C/2002 VQ94 (LINEAR): Optical spectrophotometric monitoring between 8.4 and 16.8 au from the Sun

Suchergebnisse filtern